Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Next Previous
X
Search
Trial Profile

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegadricase (Primary) ; SEL 212 (Primary) ; Sirolimus (Primary)
  • Indications Gout
  • Focus Adverse reactions
  • Sponsors Selecta Biosciences

    • Most Recent Events

    • 24 Oct 2019 According to a Selecta Biosciences media release, data from this study will be presented at the upcoming 2019 ACR Annual Meeting being held from November 8-13, 2019 in Atlanta, GA.
    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 03 Jan 2019 Results (as of October 9th, 2018) published in the Selecta Biosciences Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top